Skip to main content
Premium Trial:

Request an Annual Quote

Sentigen, Invitrogen, Mauna Kea, Thermo Fisher

Premium
Sentigen Shareholders Approve Invitrogen Acquisition
 
Sentigen Holding this week said that its stockholders have approved its planned merger with Invitrogen.
 
Sentigen said it expects the deal to close “within the next several weeks.”
 
Invitrogen said in August that it planned to acquire Sentigen, including its subsidiaries Sentigen Biosciences and Cell & Molecular Technologies, for around $25.9 million.
 

 
Invitrogen Will Co-Promote Its Imaging Reagents With Mauna Kea's Instruments
 
Mauna Kea Technologies, which sells in vivo cellular-imaging products, will jointly promote its instruments with Invitrogen reagents, the companies said this week.
 
Mauna Kea, headquartered both in Paris and Cambridge, Mass., said the combination of its fluorescence fiber optic microscopy with fluorescent reagents made by Invitrogen division Molecular Probes will allow customers to image targets of interest in living animals.
 
Invitrogen said the pairing anticipates greater demand for molecular imaging.
 
Financial terms of the agreement were not released.
 

 
Thermo Fisher Brass Adopt Plan to Sell Millions of Shares
 
Certain top executives of newly created Thermo Fisher Scientific have adopted a plan to unload millions of shares of the company’s stock, the company said this week.
 
The firm said Chairman Paul Meister plans to sell up to 2.25 million shares and CEO Marijn Dekkers plans to sell just over 1 million shares. The sale would leave Meister with 2.25 million shares and Dekkers with 2.9 million shares or equivalents.
 
Dekkers would acquire the shares he plans to sell when he exercises a stock option that was granted when he joined Thermo in 2000. The option expires in July 2007.
 
Thermo Fisher Scientific said the plan by Meister, Dekkers, and other “certain executive officers” is based on Securities and Exchange Commission stock-trading rules.
 
Thermo Electron and Fisher Scientific closed their $10.6 billion merger to create Thermo Fisher Scientific on Nov. 9.
 
Dekkers’ and Meister’s shares amount to around 2 percent of the company’s outstanding shares.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.